Purple Biotech Ltd
TASE:PPBT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
All for One Group SE
XBER:A1OS
|
DE |
|
Kanadevia Corp
OTC:HIZOF
|
JP |
Purple Biotech Ltd
Research & Development
Purple Biotech Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Purple Biotech Ltd
TASE:PPBT
|
Research & Development
-$2.4m
|
CAGR 3-Years
46%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
Research & Development
-$1B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
0%
|
CAGR 10-Years
4%
|
|
|
Sol Gel Technologies Ltd
NASDAQ:SLGL
|
Research & Development
-$24.4m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
PolyPid Ltd
NASDAQ:PYPD
|
Research & Development
-$23.8m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Mediwound Ltd
NASDAQ:MDWD
|
Research & Development
-$13.5m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-8%
|
|
|
R
|
Rekah Pharmaceutical Industry Ltd
TASE:REKA
|
Research & Development
-₪4.4m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-5%
|
|
Purple Biotech Ltd
Glance View
Purple Biotech Ltd. is a development stage pharmaceutical company, which engages in drug development. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The firm is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.
See Also
What is Purple Biotech Ltd's Research & Development?
Research & Development
-2.4m
USD
Based on the financial report for Sep 30, 2025, Purple Biotech Ltd's Research & Development amounts to -2.4m USD.
What is Purple Biotech Ltd's Research & Development growth rate?
Research & Development CAGR 3Y
46%
Over the last year, the Research & Development growth was 81%. The average annual Research & Development growth rates for Purple Biotech Ltd have been 46% over the past three years .
